This first-line protocol applies to patients with extensive-stage small cell lung cancer (SCLC) who present with brain metastases and active neurologic symptoms — a subset requiring a distinct therapeutic sequence that differs from standard extensive-stage management.
Central nervous system metastases with symptomatic neurologic involvement alter how initial therapy is sequenced. The severity of neurologic symptoms determines whether local brain-directed treatment or systemic therapy is initiated first.
In patients with symptomatic neurologic disease, brain radiation therapy is generally prioritised before systemic treatment begins, paired with initiation of corticosteroids to control cerebral oedema. Clinical circumstances may require adjusting this sequence. Once local management is addressed, combination systemic chemoimmunotherapy follows — the complete regimen options, eligibility criteria, and step-by-step algorithm are in the full protocol.
The primary objectives are disease response (complete or partial) on imaging and resolution of neurologic symptoms. Brain response is assessed by MRI or CT after defined cycles of systemic therapy.
With brain metastases
Symptomatic
Brain RT before systemic therapy, unless immediate systemic therapy is indicated
With neurologic symptoms, RT is preferred before systemic therapy.
Initiate steroids
During systemic therapy, response assessment by C/A/P CT with contrast is recommended after every 2–3 cycles of systemic therapy and at completion of therapy.
View source ↗